WU enters the week with a rare confluence: short interest at a multi-month high, borrow availability at its tightest level all year, and the stock trading at just $7.26 — down 13% over the past month.
The short side of the trade has been building with unusual urgency. Short interest climbed to 17.4% of the free float, up nearly 8% on the week and 9% over the past month — the highest reading in the 30-day window tracked here. More telling is the speed of the move: positions added roughly 2.8 million shares in a single day on June 16. That's not gradual repositioning. The ORTEX short score confirms the tone, hitting 74.8 on June 16, its highest reading in the observed history and up from 72.9 as recently as June 8.
The borrow market tells the same story, but louder. Availability has collapsed to just 36.9% — the tightest the lending pool has been all year, down from around 95% in late May. That means for roughly every three shares already borrowed, fewer than two remain available. Cost to borrow has more than doubled over the past month, reaching 1.22% — elevated for a stock this size and up 42% on the week alone. Together, these moves signal a meaningful squeeze on new shorts trying to establish or add positions: the borrow is getting harder and more expensive at exactly the moment short interest is rising. Options positioning is modestly more defensive too. The put/call ratio has drifted to 0.56, a touch above its 20-day average of 0.49, though the z-score of 1.1 stops well short of alarm. The options market is cautious, not panicked.
The Street offers little comfort to bulls. Analyst consensus formally reads "buy," but that designation reflects one outperform rating. The mean price target of $9.08 implies roughly 25% upside from current levels — yet every major firm with a recent view has either maintained or cut. Morgan Stanley, JPMorgan, and Barclays all reduced targets after Q2 2025 results and sat at Underweight into year-end. Cantor Fitzgerald initiated at Underweight in January 2026 with a $9 target. The direction of travel is clear: analysts see limited structural improvement even as they acknowledge the stock's valuation has compressed sharply. The PE multiple is now below 4x and EV/EBITDA sits at just 4.1x — each contracting over the past 30 days. Factor scores underline the division: the dividend score ranks in the 92nd percentile, and EV/EBIT scores in the 87th. But the short score ranks in the 3rd percentile, days-to-cover in the 7th. The market is paying for distress, not growth.
Institutional flows add a wrinkle worth noting. BlackRock added 7.7 million shares as of May 31 — now holding 10.2% of shares outstanding — a material addition at a firm that doesn't move passively in that size. Capital Research also added 4.2 million shares. These are not small tweaks. Whether these represent value-driven accumulation at depressed prices or index rebalancing isn't clear from the filing dates alone, but the scale sits in direct contrast to the short side's growing conviction.
Insiders have been net sellers throughout the period. The CEO sold $210,000 worth of stock in February. The CLO sold three times in May at prices around $9.20 — well above today's $7.26. The net insider direction has been outward, though values involved are small relative to the company's size.
WU reports next on July 24. The last print in April produced a muted one-day move of +0.4%, though the stock drifted 1.3% lower over the following five days. The read-through from the bear case — immigration policy headwinds, falling transaction volumes, a reduced FY2025 guidance range — remains the central debate heading into that date. What to watch between now and then is whether borrow availability recovers as existing shorts trim, or continues tightening into a stock already down sharply; the pace of that move will signal whether July's positioning is building toward a high-conviction trade or simply chasing a trend.
See the live data behind this article on ORTEX.
Open WU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
